IXC 5.26% 7.2¢ invex therapeutics ltd

Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-5

  1. 1,661 Posts.
    lightbulb Created with Sketch. 162
    The most important thing is to start! Success in EU represents half the global market and would smooth the regulatory path for the US in round two. I'm happy they are taking this lower risk approach, rather than trying to cram two competing objectives into the one trial.
 
watchlist Created with Sketch. Add IXC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.